International Association for the Study of Lung Cancer (IASLC) shared on LinkedIn:
“Advancing precision oncology starts with understanding why treatments don’t work for every patient.
Congratulations to Alessandro Leonetti, recipient of the IASLC Young Investigator Grant!
Alessandro’s project, ‘Clinical and Multi-Omics Determinants of Primary Resistance to Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer,’ seeks to identify the clinical and molecular factors that contribute to primary resistance to chemo-immunotherapy in patients with advanced NSCLC.
By uncovering why some patients do not respond to treatment, this research could help pave the way for more personalized treatment strategies and improved outcomes.
IASLC is proud to support the next generation of researchers driving innovation in thoracic oncology. Please join us in congratulating Alessandro on this well-deserved recognition!”
You might be interested in: CheckMate 77T: ctDNA Clearance and MRD Refine Risk After Perioperative Nivolumab
